Press Releases

Year

Sep 20, 2021

Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Jae Park, M.D., acting Chief of

Sep 01, 2021

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming

Aug 12, 2021

Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)

ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma Patients Phase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While Eliminating

Aug 04, 2021

Allogene Therapeutics Reports Second Quarter 2021 Financial Results

CD19 Program Highlights Phase 1 ALPHA Data at ASCO 2021 Showed a Single Dose of ALLO-501 was Associated with Overall Response, Complete Response and Durable Response Rates on Par with Autologous CD19 CAR T Therapies in CAR T Naïve Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Next CD19

Aug 02, 2021

Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors

Collective Expertise in Strategic Development and Commercialization Will Guide Preparation of the Industry’s First Potentially Pivotal Allogeneic CAR T Trial and Launch SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.

Jul 27, 2021

Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif. , July 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today

Jul 12, 2021

Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif. , July 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in two upcoming

Jun 30, 2021

Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 IGNITE Dose Escalation Trial of ALLO-605 Initiated in Q2 2021 ALLO-605 is the Third Prong of the Company’s Clinical Strategy to Target BCMA for the Treatment of Multiple Myeloma TurboCAR TM Technology Provides Selective, Programmable Cytokine Signaling Designed to Improve Function and

Jun 21, 2021

Allogene Overland Biopharm Appoints Shuyuan Yao as Chief Executive Officer

Veteran pharmaceutical executive with proven cell and gene therapy development experience in Asia , formerly of WuXi AppTec Shanghai and the joint venture JW Therapeutics SOUTH SAN FRANCISCO, Calif. & BOSTON & SHANGHAI --(BUSINESS WIRE)--Jun. 21, 2021-- Allogene Overland Biopharm (Allogene

Jun 04, 2021

Allogene Therapeutics Presents Positive Phase 1 Data on ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 Annual Meeting of the American Society of Clinical Oncology

ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrated Six Month Complete

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 25